{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"36"}],"title":"Participants who experienced toxicities"},{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"19"}],"title":"Participants who did not experience toxicities"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"55"}],"units":"Participants"}],"description":"Participants will be assessed for toxicities with the NCI-Common Terminology for Adverse Events (CTCAE), version 4.0.","groups":[{"description":"Patients receive reduced intensity or myeloablative conditioning regimen, GVHD prophylaxis, and undergo T cell depleted or no T cell depleted allogeneic SCT on day 0. After completion of study treatment, patients are followed up every 6-8 weeks for up to 24 months\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic hematopoietic stem cell transplant\n\nCliniMACS","id":"OG000","title":"Bulk SCT"},{"description":"Patients receive reduced intensity or myeloablative conditioning regimen, GVHD prophylaxis, and undergo T cell depleted or no T cell depleted allogeneic SCT on days 0, 2, 4, and 6. After completion of study treatment, patients are followed up every 6-8 weeks for up to 24 months\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic hematopoietic stem cell transplant\n\nCliniMACS","id":"OG001","title":"Fractionated SCT"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"2 years","title":"Number of Participants Assessed for Toxicities","type":"SECONDARY","unitOfMeasure":"Participants"}